Abbott’s FreeStyle Libre 3 System Receives the US FDA’s Clearance for the Treatment of Diabetes
Shots:
- The US FDA has cleared the FreeStyle Libre 3 system for diabetes in patients aged ≥4yrs. The system is expected to be available in 2022 & will be available at the same price as previous versions of the system
- The system is the world’s smallest, thinnest glucose sensor with 7.9% overall MARD that manages the patients’ health minute-by-minute. It also features improved BlueTooth integration with a range of ~33 feet
- The 14-day glucose sensor pairs with the FreeStyle Libre 3 iOS & Android mobile apps to allow users to view glucose levels in real-time, track glucose history & trends & set up optional alarms. The app allows integration with the FreeStyle digital ecosystem including LibreView & LibreLinkUp
Ref: Abbott | Image: Abbott
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
